Real Endpoints Appoints Jeff Berkowitz, CEO and Director

Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Real Endpoints’ RxScorecard™ predicted launch failure of major new anti-cholestrol drugs

Real Endpoints appoints Jane F. Barlow, MD, EVP and Chief Clinical Officer

PCSK9 class could have major impact on budgets but lack of data and comparability of drugs will allow aggressive payers to control costs: RxScorecard™ analysis

ASCO accepts Real Endpoint’s abstract on RxScorecard analysis of adjuvant breast cancer therapies

A Tale of Two New Hepatitis C Drugs

‘DrugAbacus’, a Comparative Cancer Drug Pricing Platform Powered by Real Endpoints’ RxScorecard™ is Launched